VKTXViking Therapeutics Inc

Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update PR Newswire SAN DIEGO, July 29, 2026 Conference call scheduled for 4:30 p.m. ET today-- Phase 3 VANQUISH 1...

Novo Nordisk's Q2 results are set to spotlight Ozempic and Wegovy sales as oral launches and label expansions drive growth amid mounting competitive pressure.

Biotech earnings take center stage as Viking, Biogen, Bristol Myers, Regeneron and AbbVie prepare to report Q2 2026 results.

According to the average brokerage recommendation (ABR), one should invest in Viking Therapeutics (VKTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Eli Lilly's retatrutide meets the primary endpoint in the phase III TRIUMPH-2 & TRIUMPH-3 studies, supporting planned regulatory submissions for obesity in 2027.

Viking Therapeutics, Inc. (VKTX) reached $35.39 at the closing of the latest trading day, reflecting a -5.15% change compared to its last close.

LLY's blockbuster GLP-1 portfolio takes center stage as investors watch Mounjaro, Zepbound and Foundayo for clues to Q2 growth and outlook.

Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors PR Newswire SAN DIEGO,, July 23, 2026 Experienced Executive Brings Over Two Decades of Leadership Across Healthcare, Digital Health and CommercializationSAN DIEGO...

Drugmakers have announced 37 biotech acquisitions worth at least $1 billion this year, topping the previous annual record.